Cessation of Immunomodulatory Medication Use in Dermatomyositis: A Single‐Center Cohort Study
Authors' conclusion
Approximately 20% of adult DM patients discontinued immunomodulatory medications over a median 7-year follow-up. Those with clinically amyopathic disease, anti-MDA5, anti-NXP2, and anti-SAE1 antibodies have a higher likelihood of medication cessation.
Study context
- Population
- Adult dermatomyositis (DM) patients seen in a rheumatology/dermatology clinic, 2013–2020, exposed to ≥1 systemic immunomodulatory medication for ≥3 monthsmedian follow-up ∼7 years
- Participants
- 246 participants
- Exposure
- Clinical and autoantibody subgroups of adult DM, for discontinuation of systemic immunomodulatory therapy
- Outcome
- Discontinuation of all immunomodulatory medications for at least 12 months
Methodological detailssingle-centre, Kaplan-Meier with log-rank analyses, Cox proportional hazards models
- Single-centre
- Kaplan-Meier with log-rank analyses
- Cox proportional hazards models
Main finding
As reported in the abstract
Discontinued all immunomodulatory medications
All DM patients
19%
47 events
Observational data: associations, not effects.
Further findings
| Outcome | HR (95% CI) | |
|---|---|---|
| Medication cessation by autoantibody (multivariate)Anti-MDA5vs Autoantibody-negative | 9.83 (2.00–48.2) | |
| Medication cessation by autoantibody (multivariate)Anti-NXP2vs Autoantibody-negative | 8.92 (1.69–47.0) | |
| Medication cessation by autoantibody (multivariate)Anti-SAE1vs Autoantibody-negative | 10.8 (2.06–56.6) | |
| 0.050.21520Hazard ratio (log scale) |
| Outcome | Fold more likely (95% CI) | P value |
|---|---|---|
| Medication cessation by clinical phenotype (multivariate)Clinically amyopathic vs Muscle disease | 2.7 (1.34–5.59) | |
| Time to medication discontinuation (log-rank)Anti-MDA5 vs Autoantibody-negative · anti-MDA5 discontinued medications faster | P = 0.03 |
Original publication
Cessation of Immunomodulatory Medication Use in Dermatomyositis: A Single‐Center Cohort Study. Arthritis Care Res (Hoboken). Published 18 January 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →